GALECTIN THERAPEUTICS INC - COM NEW (GALT)

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class
Equity / COM NEW
Total 13F shares
10,463,242
Share change
+555,804
Total reported value
$22,085,893
Put/Call ratio
262%
Price per share
$2.11
Number of holders
84
Value change
+$1,798,912
Number of buys
37
Number of sells
37

Institutional Holders of GALECTIN THERAPEUTICS INC - COM NEW (GALT) as of Q2 2025

As of 30 Jun 2025, GALECTIN THERAPEUTICS INC - COM NEW (GALT) was held by 84 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 10,463,242 shares. The largest 10 holders included VANGUARD GROUP INC, OSAIC HOLDINGS, INC., BlackRock, Inc., JANE STREET GROUP, LLC, GEODE CAPITAL MANAGEMENT, LLC, Wealthspire Advisors, LLC, Geneos Wealth Management Inc., LPL Financial LLC, COMMONWEALTH EQUITY SERVICES, LLC, and MORGAN STANLEY. This page lists 85 institutional shareholders reporting positions in this security for the Q2 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.